Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Chill Brands [stock_market_widget type=”chart” template=”line” assets=”CHLL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The CBD and vaping retailer Chill Brands has voted to oust two of its longest-standing directors as part of an investor coup.
Last week, UK biotechnology firm Oxford Cannabinoid Technologies (OCT), one of the first cannabis companies in history to list on the London Stock Exchange (LSE), informed investors of its intention to leave.
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.DE” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group SynBiotic has capitalised on the recent explosion in medical cannabis patients since the country’s landmark CanG came into effect last month.
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”line” assets=”OCTP.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a second compound after partnering with Australian contract research organisation (CRO) iNGENū.
MGC Pharmaceuticals / Argent BioPharma [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals has become the latest UK-listed cannabis company to opt for a rebrand in 2024, as businesses increasingly try to diversify and distance themselves from the difficulties experienced across the cannabis sector over the last year…
Cellular Goods (Cel AI) [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”CBX.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Cellular Goods has this morning announced another major pivot in its strategy, just days after its former CEO, who himself attempted to diversify the brand’s operations away from beauty, left the company.
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed.
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I clinical trial had been administered, with no ‘drug adverse effects observed’.
